Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 07, 2024

SELL
$102.5 - $123.59 $16.5 Million - $19.9 Million
-160,978 Reduced 39.99%
241,588 $29.3 Million
Q3 2023

Nov 13, 2023

SELL
$102.5 - $123.59 $16.5 Million - $19.9 Million
-160,978 Reduced 39.99%
241,588 $29.3 Million
Q2 2023

Oct 07, 2024

SELL
$106.4 - $157.19 $20.5 Million - $30.3 Million
-192,640 Reduced 32.37%
402,566 $46.1 Million
Q2 2023

Aug 14, 2023

SELL
$106.4 - $157.19 $20.5 Million - $30.3 Million
-192,640 Reduced 32.37%
402,566 $46.1 Million
Q1 2023

Oct 07, 2024

SELL
$117.53 - $155.99 $54.6 Million - $72.4 Million
-464,366 Reduced 43.83%
595,206 $82 Million
Q1 2023

May 12, 2023

SELL
$117.53 - $155.99 $54.6 Million - $72.4 Million
-464,366 Reduced 43.83%
595,206 $82 Million
Q4 2022

Oct 07, 2024

BUY
$100.86 - $132.13 $107 Million - $140 Million
1,059,572 New
1,059,572 $137 Million
Q4 2022

Feb 10, 2023

SELL
$100.86 - $132.13 $468,192 - $613,347
-4,642 Reduced 0.44%
1,059,572 $137 Million
Q3 2022

Nov 14, 2022

BUY
$75.71 - $119.24 $56 Million - $88.3 Million
740,283 Added 228.53%
1,064,214 $118 Million
Q2 2022

Aug 12, 2022

BUY
$62.69 - $88.44 $698,930 - $986,017
11,149 Added 3.56%
323,931 $24.3 Million
Q1 2022

May 13, 2022

SELL
$63.15 - $90.42 $31.1 Million - $44.5 Million
-492,198 Reduced 61.14%
312,782 $24.4 Million
Q4 2021

Feb 11, 2022

BUY
$77.28 - $99.42 $62.2 Million - $80 Million
804,980 New
804,980 $72.5 Million
Q1 2021

May 11, 2021

SELL
$72.25 - $168.95 $19.7 Million - $46.2 Million
-273,268 Closed
0 $0
Q4 2020

Feb 09, 2021

SELL
$125.56 - $178.74 $1.62 Million - $2.31 Million
-12,939 Reduced 4.52%
273,268 $46.6 Million
Q3 2020

Nov 12, 2020

SELL
$127.12 - $172.34 $387,207 - $524,947
-3,046 Reduced 1.05%
286,207 $40.2 Million
Q2 2020

Aug 14, 2020

BUY
$93.0 - $171.7 $6.05 Million - $11.2 Million
65,009 Added 28.99%
289,253 $46.4 Million
Q1 2020

May 14, 2020

BUY
$82.38 - $131.64 $3.96 Million - $6.33 Million
48,052 Added 27.27%
224,244 $21.9 Million
Q4 2019

Feb 14, 2020

BUY
$76.53 - $135.58 $3.94 Million - $6.98 Million
51,493 Added 41.29%
176,192 $22.7 Million
Q3 2019

Nov 14, 2019

SELL
$72.81 - $156.91 $14.5 Million - $31.2 Million
-198,854 Reduced 61.46%
124,699 $9.39 Million
Q2 2019

Aug 14, 2019

BUY
$112.21 - $151.95 $27,491 - $37,227
245 Added 0.08%
323,553 $49.2 Million
Q1 2019

May 15, 2019

SELL
$106.67 - $151.68 $860,400 - $1.22 Million
-8,066 Reduced 2.43%
323,308 $38.5 Million
Q4 2018

Feb 14, 2019

SELL
$97.32 - $148.76 $9.02 Million - $13.8 Million
-92,646 Reduced 21.85%
331,374 $36.2 Million
Q3 2018

Nov 14, 2018

SELL
$115.31 - $161.51 $12.9 Million - $18.1 Million
-112,213 Reduced 20.93%
424,020 $68.5 Million
Q2 2018

Aug 14, 2018

BUY
$71.74 - $153.69 $9.93 Million - $21.3 Million
138,381 Added 34.78%
536,233 $70.9 Million
Q1 2018

May 15, 2018

SELL
$54.02 - $82.27 $7.53 Million - $11.5 Million
-139,422 Reduced 25.95%
397,852 $29.5 Million
Q4 2017

Feb 14, 2018

SELL
$47.64 - $56.75 $2.34 Million - $2.79 Million
-49,131 Reduced 8.38%
537,274 $29.9 Million
Q3 2017

Nov 14, 2017

BUY
$35.73 - $47.15 $21 Million - $27.6 Million
586,405
586,405 $26.6 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.96B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.